Bulletin
Investor Alert

Caribou Biosciences Inc.

NAS: CRBU

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Aug 18, 2022, 6:15 p.m.

/zigman2/quotes/228313444/composite

$

9.82

Change

-0.51 -4.94%

Volume

Volume 14,173

Quotes are delayed by 20 min

/zigman2/quotes/228313444/composite

Today's close

$ 10.41

$ 10.33

Change

-0.08 -0.77%

Day low

Day high

$9.68

$10.48

Open

52 week low

52 week high

$4.89

$32.65

Open

Company Description

Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. Its tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial ...

Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. Its tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology. The company was founded by Jennifer A. Doudna, Rachel E. Haurwitz, Martin Jinek and James Berger on October 28, 2011 and is headquartered in Berkeley, CA.

Valuation

Price to Sales Ratio

94.75

Price to Book Ratio

2.34

Enterprise Value to EBITDA

-3.91

Enterprise Value to Sales

19.25

Efficiency

Total Asset Turnover

0.04

Liquidity

Current Ratio

15.15

Quick Ratio

15.15

Cash Ratio

14.55

Profitability

Gross Margin

89.75

Operating Margin

-697.84

Pretax Margin

-693.92

Net Margin

-697.26

Return on Assets

-27.67

Return on Equity

-36.73

Return on Total Capital

-32.85

Capital Structure

Total Debt to Total Assets

0.06

Officers and Executives

Name Age Officer Since Title
Dr. Rachel E. Haurwitz 35 2011 Founder
Mr. Jason O’Byrne - 2021 Chief Financial Officer
Dr. Steven B. Kanner 61 2017 Chief Scientific Officer
Ms. Cherry T. Thomas - - Senior Vice President-Clinical Development
Dr. Syed Rizvi - 2022 Chief Medical Officer

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
05/13/2022 Steven B. Kanner
Chief Scientific Officer
6,114   Derivative/Non-derivative trans. at $2.69 per share. 16,446
05/13/2022 Steven B. Kanner
Chief Scientific Officer
68,306   Derivative/Non-derivative trans. at $1.81 per share. 123,633
05/09/2022 Rachel E. Haurwitz
President and CEO; Director
10,000   Derivative/Non-derivative trans. at $2.96 per share. 29,600
05/05/2022 Ryan Fischesser
VP of Finance and Controller
1,138   Derivative/Non-derivative trans. at $4.11 per share. 4,677
05/05/2022 Ryan Fischesser
VP of Finance and Controller
1,136   Derivative/Non-derivative trans. at $2.69 per share. 3,055
03/15/2022 Ryan Fischesser
VP of Finance and Controller
1,138   Derivative/Non-derivative trans. at $4.11 per share. 4,677
03/15/2022 Ryan Fischesser
VP of Finance and Controller
1,136   Derivative/Non-derivative trans. at $2.69 per share. 3,055
03/04/2022 Steven B. Kanner
Chief Scientific Officer
1,549   Derivative/Non-derivative trans. at $4.11 per share. 6,366
03/04/2022 Steven B. Kanner
Chief Scientific Officer
9,171   Derivative/Non-derivative trans. at $2.69 per share. 24,669
02/08/2022 Jason O’Byrne
Chief Financial Officer
24,336   Derivative/Non-derivative trans. at $4.11 per share. 100,020
01/26/2022 Rachel E. Haurwitz
President and CEO; Director
10,000   Derivative/Non-derivative trans. at $2.96 per share. 29,600
01/26/2022 Rachel E. Haurwitz
President and CEO; Director
10,000   Derivative/Non-derivative trans. at $2.96 per share. 29,600
01/25/2022 Syed Rizvi
Chief Medical Officer
60,000   Award at $0 per share. 0
01/11/2022 Ryan Fischesser
VP of Finance and Controller
6,818   Acquisition at $4.11 per share. 28,021
01/11/2022 Ryan Fischesser
VP of Finance and Controller
569   Acquisition at $2.69 per share. 1,530
12/20/2021 Ryan Fischesser
VP of Finance and Controller
1,136   Acquisition at $2.69 per share. 3,055
/news/latest/company/us/crbu

MarketWatch News on CRBU

  1. Gene-Editor Crispr Therapeutics CEO Sees Positive Catalysts Ahead

    4:25 p.m. June 23, 2022

    - Barron's Online

  2. These 3 Funds Invest Like ARK But Didn’t Fall as Far

    12:32 a.m. Feb. 12, 2022

    - Barron's Online

  3. Caribou Biosciences started at outperform with $36 stock price target at Oppenheimer

    8:34 a.m. Dec. 1, 2021

    - Tomi Kilgore

  4. Prime Is the Newest Gene Editing, and It's Getting Better

    7:11 p.m. Oct. 20, 2021

    - Barron's Online

  5. Caribou Biosciences started at buy with $30 stock price target at BofA Securities

    10:23 a.m. Aug. 17, 2021

    - Tomi Kilgore

  6. 7 Companies Open for Trading. Here's How They Did.

    4:58 p.m. July 23, 2021

    - Barron's Online

/news/nonmarketwatch/company/us/crbu

Other News on CRBU

  1. Caribou Biosciences (CRBU) Corporate Presentation - Slideshow

    6:39 p.m. Aug. 17, 2022

    - Seeking Alpha

  2. Caribou Biosciences: Potential To Change CAR-T Landscape

    2:19 p.m. Aug. 1, 2022

    - Seeking Alpha

  3. Caribou Biosciences (CRBU) Corporate Presentation - Slideshow

    6:18 p.m. June 10, 2022

    - Seeking Alpha

  4. HYMC, AXLA and EVLO among mid-day gainers

    12:49 p.m. June 10, 2022

    - Seeking Alpha

  5. Crispred CAR-T Cells In The Clinic

    7:44 a.m. May 19, 2022

    - Seeking Alpha

  6. The Correction In Biopharmaceutical Stocks Is Likely Over

    12:51 a.m. May 18, 2022

    - Seeking Alpha

  7. Caribou Biosciences (CRBU) Investor Presentations - Slideshow

    5:51 p.m. May 17, 2022

    - Seeking Alpha

  8. Caribou Charges Ahead on Study Results

    2:07 p.m. May 17, 2022

    - GuruFocus.com

  9. Loading more headlines...

At a Glance

Caribou Biosciences, Inc.

2929 7th Street

Suite 105

Berkeley, California 94710

Phone

1 5109826030

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2022

Revenue

$9.60M

Net Income

$-66.92M

Employees

99.00

/news/pressrelease/company/us/crbu

Press Releases on CRBU

  1. Friday Sector Laggards: Biotechnology, Drugs

    12:11 p.m. June 10, 2022

    - MarketNewsVideo.com

  2. Caribou Biosciences to Present at Upcoming Investor Conferences

    5:11 p.m. March 7, 2022

    - GlobeNewswire

  3. Thursday 1/13 Insider Buying Report: IDEX, CRBU

    3:06 p.m. Jan. 13, 2022

    - MarketNewsVideo.com

  4. Caribou Biosciences to Present at Upcoming Investor Conferences

    5:05 p.m. Nov. 17, 2021

    - GlobeNewswire

  5. Loading more headlines...
Link to MarketWatch's Slice.